Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722775 | 0.91 | PTGS2 (0.51) | PTGS2PTGS1S1PR1PIK3CDPIK3CA | |
| SCHEMBL6733105 | 0.88 | PTGS2 (0.48) | PTGS2PTGS1S1PR1DHODH | |
| SCHEMBL6729970 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6729126 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6725820 | 0.82 | PTGS2 (0.54) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7047515 | 0.82 | PTGS2 (0.42) | PTGS2ALOX5APFEN1 | |
| SCHEMBL6723198 | 0.82 | PTGS2 (0.45) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6725499 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1DHODH | |
| SCHEMBL6730144 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7046231 | 0.81 | SYK (0.40) | PTGS2PTGS1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20030232996-A1 | Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
| US-6600052-B1 | With a ring cyclizing reagent to form the compound of Formula V to yield a compound of Formula V: inhibitors of the cyclooxygenase- II enzyme. and antiinflammatory agents and analgesic pharmaceutical agents. | PHARMACIA CORPORATION | 2003-07-29 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885S1PR1 199/4885 |
| US-20030232996-A1 | Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes | CCNE2, CCNC, CYP3A4 | PTGS2 784/4885PTGS1 1072/4885S1PR1 2396/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885S1PR1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.